SEATTLE, March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. With these data and the previously announced successful single-ascending-dose portion of this clinical trial, Omeros is advancing OMS824 toward a Phase 2 clinical program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.
The OMS824 Phase 1 clinical trial was a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study. The trial enrolled 64 healthy male subjects; 40 subjects received a single dose and 24 subjects received daily dosing for 7 to 10 days. OMS824 was well tolerated by all subjects, and the only apparent drug-related adverse event was mild somnolence at the highest dose evaluated. No subject had extrapyramidal symptoms (e.g., involuntary muscle movements), which are associated with marketed antipsychotic medications and have been seen with other companies' PDE10 inhibitors at levels of approximately 50-percent engagement of the PDE10 enzyme in the brain. A radiotracer imaging study is underway to confirm the target engagement of OMS824 in human brains.
The study results showed that the pharmacokinetic parameters (Cmax and AUC) increased linearly with the dose and that OMS824 had a long half-life that is consistent with once daily dosing. OMS824 was detected in the cerebrospinal fluid at the expected concentration relative to that in the blood. The drug concentration in the cerebrospinal fluid is predicted to achieve near-complete inhibition of the PDE10 target in the brain. These results show that OMS824, at well-tolerated doses, achieves concentrations that are anticipated to effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.
"These results are exciting – it appears that OMS824 is able to achieve significantly higher concentrations at the target enzyme in the brain than other PDE10 inhibitors being developed across the industry without incurring the movement abnormalities seen with those other compounds," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While wrapping up the Phase 1 program, we are aggressively advancing OMS824 into Phase 2 trials. Our initial focus will be Huntington's disease, for which we will be requesting orphan drug as well as Fast Track designations from the FDA, and a Phase 2a trial in patients with schizophrenia is expected to follow shortly thereafter. In addition to our progress in the OMS824 program, we plan to submit the NDA next quarter and the MAA mid-year for OMS302, our ophthalmic drug product, and we remain on track to advance our MASP-2 and PDE7 programs into the clinic in the coming months."
About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Cognitive dysfunction is responsible for substantial disability in these diseases and is not improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve psychiatric manifestations, such as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding the potential qualities of OMS824; that it will request orphan drug and Fast Track designations for OMS824; that it will advance OMS824 into a Phase 2 clinical program; that it will submit an NDA and MAA for OMS302 this year; that it will advance its MASP-2 and PDE7 programs into the clinic in the coming months; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
SOURCE Omeros Corporation
Jennifer Cook Williams, Investor and Media Relations, Cook Williams Communications, Inc., 360.668.3701, email@example.com